AIDS 2024: No Confirmed Virological Failures (CVF) for 144 weeks when Switching 2-/3-/4-drug ART to DTG/3TC in Heavily Treatment-experienced PLWHA with Prior M184V/I and Virological Failures (VF) in the Prospective Solar-3D Study
Speaker: Gary Blick
The study investigated whether switching to a two-drug therapy off-label for patients with prior M184V mutations and virological failures was as effective without compromising virological efficacy. The study highlighted that a two-drug regimen could replace the four-drug therapy without additional safety concerns and significantly benefit economically developing countries by discontinuing costly drugs like abacavir, Tenofovir Disoproxil Fumarate (TDF), and Tenofovir Alafenamide (TAF).
One of the labels restricted its use to patients without prior virological failures or resistance to Dolutegravir (DTG)/Lamivudine (3TC) components. This limitation meant that 70% of the practice's patients, who were heavily treatment-experienced, could not qualify for the switch, representing an unmet need. Initial hesitance was due to perceived insufficient data. Still, studies including Solar three-dimension (3D), Antiretroviral therapy (ART) Pro, and Volvo, along with a recent meta-analysis, demonstrated that DTG/3TC could maintain virological suppression in 96 to 100% of patients with M184V mutations. The rationale for the study included 3TC's modest antiviral effect even with M184V, the reduced viral replication capacity associated with M184V, and the potential long-term safety and cost benefits of a two-drug regimen over TDF-based therapies.
The study, conducted by Healthcare Advocates International, enrolled patients from June 2019 to 2020. It was a prospective, open-label comparative study initially planned for 96 weeks but extended to 144 weeks due to observed safety. The study included patients with prior virological failures despite this being against the label. Initially, 20 patients per arm were enrolled, increasing to 100 per arm after assessing safety, with an additional 50 patients in the non-historical M184V arm. The study included patients regardless of prior drug use and analyzed baseline characteristics showing significant differences between those with and without prior M184V mutations. The median time since Human Immunodeficiency Virus (HIV) diagnosis was nearly 30 years, with a median Antiretroviral therapy (ART) 25 years and an average of 9 prior virological regimens.
The study found that one-third of patients with M184V had the mutation in their proviral Deoxyribonucleic Acid (DNA), while none of the non-historical M184V group had it. The ART regimens were complex, with 72% of the M184V group having prior Integrase Strand Transfer Inhibitor (INSTI) use, mainly raltegravir and elvitegravir.
The virological outcomes at 144 weeks showed no significant differences between the M184V and non-historical M184V groups. By intent-to-treat analysis, polymerase chain reaction (PCR) results in≥50 copies, which were similar in both groups. For secondary endpoints, PCR <50 copies also showed no differences. The per-protocol analysis confirmed these results, with no significant differences in PCR ≥50 copies or PCR <50 copies. Viral dispositions revealed that patients who lost follow-up were not different in virological outcomes. One confirmed virological failure in the M184V group but none in the non-historical M184V group. No cases of treatment-emergent resistance were observed. Viral blips and viral load <20 copies were similar across both groups through 144 weeks.
Adverse events in patients on dolutegravir-based regimens were typical and infrequent. Notably, one patient in the M184V arm withdrew due to light-headedness and vertigo, which she attributed to the drug. Serious adverse events were reported but were not significant.
In conclusion, the Solar 3D trial was the longest prospective comparative study to date, demonstrating that neither prior nor current M184V mutations nor prior virological failures significantly affected the efficacy or durability of switching virologically suppressed patients to DTG/3TC over 3 years. The potential benefits of transitioning from TDF-containing regimens to a two-drug regimen include significant cost savings and reduced morbidity and mortality, particularly in economically developing countries. Further exploration is needed to assess the impact of discontinuing TDF, especially in regions with high K65R prevalence.
The 25th International AIDS conference (AIDS 2024). 22nd-26th July, Munich, Germany


